The RCP Test™ and Detecting
Women’s Reproductive Cancers
Frequently undiagnosed, women’s reproductive cancers - including ovarian, uterine and cervical cancer – often go undetected in their early stages, allowing the cancer to spread and causing high mortality rates. To fight these deadly diseases, Provista Life Sciences has created the
RCP Test, a testing service for women’s reproductive cancers that combats the lack of quality testing options available today.
With the goal of narrowing the timeframe between cancer incidence and cancer detection, the RCP Test offers a unique opportunity for physicians to drastically improve their patients’ treatment outcomes.
When used in conjunction with other
early detection methods , such as mammograms and Pap smears, this simple blood test can help doctors accurately diagnose cancer sooner. The RCP Test measures molecular markers for the presence of a tumor in a noninvasive, effective way, offering fewer false negatives, fewer false positives and consistent results.
Learn more about women’s cancers and treatments and the science behind the RCP Test with the links below.
About Women’s Cancers
RCP Test Research